However, at the current doses, SASP and ACC promoted the expressions of JAK1 (Figure 5(h)) and JAK3 (Figure 5(j)), and ACC displayed a negative regulatory effect on JAK1-JAK3. The gene discussed is JAK3; the disease is adrenal cortex carcinoma.